Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information (Tables)

v3.25.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Reconciles Segment Direct Profit or Loss

The following table reconciles segment direct profit or loss to the Company’s consolidated results:

 

 

Year Ended December 31,

 

(in thousands)

2024

 

 

2023

 

Research and development:

 

 

 

 

 

QTORIN rapamycin for PC and GS

$

 

 

$

3,682

 

QTORIN rapamycin for microcystic LM

 

1,929

 

 

 

164

 

QTORIN rapamycin for microcystic LM - Government grant income

 

(141

)

 

 

 

QTORIN rapamycin for cutaneous VM

 

296

 

 

 

 

QTORIN rapamycin CMC

 

1,601

 

 

 

878

 

Non-program specific and unallocated research and development expenses:

 

 

 

 

 

Salaries and stock-based compensation

 

2,810

 

 

 

2,383

 

Consultants

 

1,040

 

 

 

1,229

 

Other

 

616

 

 

 

457

 

Total research and development

$

8,151

 

 

$

8,793

 

General and administrative:

 

 

 

 

 

Salaries and stock-based compensation

$

1,935

 

 

$

821

 

Consultants

 

2,961

 

 

 

605

 

Other

 

1,048

 

 

 

1,650

 

Total general and administrative

$

5,944

 

 

$

3,076

 

Loss from operations

$

(14,095

)

 

$

(11,869

)